{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:03:55Z","timestamp":1768406635471,"version":"3.49.0"},"reference-count":24,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2024.14603","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T06:41:19Z","timestamp":1722408079000},"source":"Crossref","is-referenced-by-count":2,"title":["Pembrolizumab therapy in a patient with NSCLC and bullous pemphigoid: A case report"],"prefix":"10.3892","volume":"28","author":[{"given":"Ang","family":"Li","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fasheng","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhipeng","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutao","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyun","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhu","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"key20240906090816_b1-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","article-title":"Immunotherapy in non-small cell lung cancer: Facts and hopes","volume":"25","author":"Doroshow","year":"2019","journal-title":"Clin Cancer Res"},{"key":"key20240906090816_b2-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"key20240906090816_b3-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"key20240906090816_b4-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1200\/JCO.2022.40.16_suppl.9004","article-title":"Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A","volume":"40","author":"Reckamp","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20240906090816_b5-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1111\/1759-7714.14113","article-title":"Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy","volume":"12","author":"Xing","year":"2021","journal-title":"Thorac Cancer"},{"key":"key20240906090816_b6-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: Pemphigus and bullous pemphigoid","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"key20240906090816_b7-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1111\/ijd.15366","article-title":"Pembrolizumab-induced reactivation of bullous pemphigoid","volume":"60","author":"Kaul","year":"2021","journal-title":"Int J Dermatol"},{"key":"key20240906090816_b8-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/art.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: A nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"key20240906090816_b9-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3322\/caac.21390","article-title":"Lung cancer-major changes in the American joint committee on cancer eighth edition cancer staging manual","volume":"67","author":"Rami-Porta","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"key20240906090816_b10-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20240906090816_b11-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3322\/caac.20005","article-title":"Cutaneous manifestations of internal malignancy","volume":"59","author":"Thiers","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"key20240906090816_b12-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/ajd.12764","article-title":"Association between bullous pemphigoid and malignancy: A meta-analysis","volume":"59","author":"Lucariello","year":"2018","journal-title":"Australas J Dermatol"},{"key":"key20240906090816_b13-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4103\/0022-3859.150906","article-title":"A case of paraneoplastic bullous pemphigoid in association with squamous cell carcinoma of lung","volume":"61","author":"Das","year":"2015","journal-title":"J Postgrad Med"},{"key":"key20240906090816_b14-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"e32822","DOI":"10.1097\/MD.0000000000032822","article-title":"A case report of paraneoplastic bullous pemphigoid associated with mantle cell lymphoma: A rare presentation","volume":"102","author":"Md Radzi","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"key20240906090816_b15-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"adv00289","DOI":"10.2340\/00015555-3622","article-title":"Increased risk of squamous cell carcinoma of the skin and lymphoma among 5,739 patients with bullous pemphigoid: A Swedish nationwide cohort study","volume":"100","author":"Albadri","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"key20240906090816_b16-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/1346-8138.13079","article-title":"Malignancies in bullous pemphigoid: A controversial association","volume":"43","author":"Balestri","year":"2016","journal-title":"J Dermatol"},{"key":"key20240906090816_b17-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/biom10101432","article-title":"Bullous pemphigoid: Trigger and predisposing factors","volume":"10","author":"Moro","year":"2020","journal-title":"Biomolecules"},{"key":"key20240906090816_b18-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant Nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"key20240906090816_b19-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20240906090816_b20-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.lungcan.2019.05.029","article-title":"Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis","volume":"134","author":"Dafni","year":"2019","journal-title":"Lung Cancer"},{"key":"key20240906090816_b21-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.jtho.2021.03.016","article-title":"Efficacy and safety of first-line immunotherapy combinations for advanced NSCLC: A systematic review and network meta-analysis","volume":"16","author":"Liu","year":"2021","journal-title":"J Thorac Oncol"},{"key":"key20240906090816_b22-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N Engl J Med"},{"key":"key20240906090816_b23-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1177\/1758834016644155","article-title":"Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: Latest evidence about its extended use and outcomes","volume":"8","author":"Tomasini","year":"2016","journal-title":"Ther Adv Med Oncol"},{"key":"key20240906090816_b24-ol-28-4-14603","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T06:08:23Z","timestamp":1725602903000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2024.14603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,7,31]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2024.14603","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"article-number":"470"}}